Introduction
anti-PEG-Loxe, weight gain, overweight, weight loss, T2DM
TYPE 2 DIABETES MELLITUS, OBESE, SIDE EFFECT
Type 2 diabetes mellitus (T2DM) is commonly associated with being overweight or obese. In China, more than half of patients with T2DM are overweight or obese (Weight management is a vital aspect of treatment for patients with T2DM. However, weight gain is a side effect of some antidiabetic drugs, including thiazolidinedione, sulfonylurea, glinide, and insulin (GLP-1RAs are a relatively new class of drugs used to treat T2DM in the general population. The primary function of GLP-1RA is to improve glucose metabolism by increasing pancreatic β-cell insulin secretion and reducing α-cell glucagon secretion. Another well-known effect of GLP-1RA is weight loss through appetite suppression and reduced food intake (Polyethylene glycol loxenatide (PEG-Loxe) is a novel GLP-1RA derived from exendin-4, with 53% homology to human GLP-1 and an anti-PEG-Loxe antibody positive rate of < 2% (